Toxicogenomic and bioinformatics platforms to identify key molecular mechanisms of a curcumin-analogue DM-1 toxicity in melanoma cells

Autor(es):Mostrar menos -

de Oliveira, Erica Aparecida ; de Lima, Diogenes Saulo ; Cardozo, Lucas Esteves ; de Souza, Garcia Ferreira ; de Souza, Nayane ; Alves-Fernandes, Debora Kristina ; Faiao-Flores, Fernanda ; Pablo Quincoces, Jose Agustin ; de Moraes Barros, Silvia Berlanga ; Nakaya, Helder I. ; Monteiro, Gisele ; Maria-Engler, Silvya Stuchi

• Tipo de documento: Artigo Científico
• Fonte: PHARMACOLOGICAL RESEARCH; v. 125, p. 10-pg., 2017-11-01.

Resumo

Melanoma is a highly invasive and metastatic cancer with high mortality rates and chemoresistance. Around 50% of melanomas are driven by activating mutations in BRAF that has led to the development of potent anti-BRAF inhibitors. However resistance to anti-BRAF therapy usually develops within a few months and consequently there is a need to identify alternative therapies that will bypass BRAF inhibitor resistance. The curcumin analogue DM-1 (sodium 4-[5-(4-hydroxy-3-methoxy-phenyl)-3-oxo-penta-1,4-dieny1]-2-methoxy-phenolate) has substantial anti-tumor activity in melanoma, but its mechanism of action remains unclear. Here we use a synthetic lethal genetic screen in Saccharomyces cerevisiae to identify 211 genes implicated in sensitivity to DM-1 toxicity. From these 211 genes, 74 had close human orthologues implicated in oxidative phosphorylation, insulin signaling and iron and RNA metabolism. Further analysis identified 7 target genes (ADIC, ATP6V0B, PEMT, TOP1, ZFP36, ZFP36L1, ZFP36L2) with differential expression during melanoma progression implicated in regulation of tumor progression, cell differentiation, and epithelial-mesenchymal transition. Of these TOP1 and ADK were regulated by DM-1 in treatment-naive and vemurafenib-resistant melanoma cells respectively. These data reveal that the anticancer effect of curcumin analogues is likely to be mediated via multiple targets and identify several genes that represent candidates for combinatorial targeting in melanoma. (C) 2017 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 14/24400-0 - Modelos in vitro para estudos pré-clínicos de melanoma quimioresistente
• Beneficiário: Silvya Stuchi Maria-Engler
• Modalidade de apoio: Auxílio à Pesquisa - Regular